Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif.
| Revenue (Most Recent Fiscal Year) | $10.59M |
| Net Income (Most Recent Fiscal Year) | $-68.99M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 109.02 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.40 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -832.71% |
| Net Margin (Trailing 12 Months) | -463.91% |
| Return on Equity (Trailing 12 Months) | -9.29% |
| Return on Assets (Trailing 12 Months) | -8.89% |
| Current Ratio (Most Recent Fiscal Quarter) | 58.47 |
| Quick Ratio (Most Recent Fiscal Quarter) | 58.47 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $17.11 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.38 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.28 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.36 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 59.17M |
| Free Float | 54.38M |
| Market Capitalization | $1.42B |
| Average Volume (Last 20 Days) | 1.24M |
| Beta (Past 60 Months) | 3.24 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 75.39% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |